Filtered By:
Source: Vaccine
Vaccination: Covid Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1290 results found since Jan 2013.
Review: Factors influencing parents' decisions to vaccinate children against COVID-19
CONCLUSION: This review identified critical factors affecting parents' vaccination behavior for their children. Awareness of these factors may reduce parents' COVID-19 vaccine refusal for their children and guide future planning and development of public health studies.PMID:37735055 | DOI:10.1016/j.vaccine.2023.09.020
Source: Vaccine - September 21, 2023 Category: Allergy & Immunology Authors: Haifa S Alharbi Source Type: research
A large survey on COVID-19 vaccination in patients with Parkinson's disease and healthy population
CONCLUSIONS: The COVID-19 vaccination rate was remarkably lower in PD patients than healthy individuals in China. The approved vaccines have shown an acceptable safety profile. Our findings would offer a reference to guide future clinical decision-making of COVID-19 vaccination and improve the immunization management of PD patients.PMID:37726180 | DOI:10.1016/j.vaccine.2023.09.002
Source: Vaccine - September 19, 2023 Category: Allergy & Immunology Authors: Chao Han Zhen Zhen Zhao Piu Chan Fang Li Chun Ling Chi Xin Zhang Yan Zhao Jing Chen Jing Hong Ma Source Type: research
Preclinical evaluation of a SARS-CoV-2 variant B.1.351-based candidate DNA vaccine
Vaccine. 2023 Sep 17:S0264-410X(23)01091-5. doi: 10.1016/j.vaccine.2023.09.021. Online ahead of print.ABSTRACTThe SARS-CoV-2 pandemic revealed the critical shortfalls of global vaccine availability for emergent pathogens and the need for exploring additional vaccine platforms with rapid update potential in response to new variants. Thus, it remains essential, for the present evolving SARS-CoV-2/Covid-19 and future pandemics, to continuously develop and characterize new and different vaccine platforms. Here, we describe an expression-optimized DNA vaccine candidate based on the SARS-CoV-2 spike protein of the Beta variant (...
Source: Vaccine - September 19, 2023 Category: Allergy & Immunology Authors: Ria Lassauni ère Charlotta Polacek Jeanette Linnea Tingstedt Anders Fomsgaard Source Type: research
A large survey on COVID-19 vaccination in patients with Parkinson's disease and healthy population
CONCLUSIONS: The COVID-19 vaccination rate was remarkably lower in PD patients than healthy individuals in China. The approved vaccines have shown an acceptable safety profile. Our findings would offer a reference to guide future clinical decision-making of COVID-19 vaccination and improve the immunization management of PD patients.PMID:37726180 | DOI:10.1016/j.vaccine.2023.09.002
Source: Vaccine - September 19, 2023 Category: Allergy & Immunology Authors: Chao Han Zhen Zhen Zhao Piu Chan Fang Li Chun Ling Chi Xin Zhang Yan Zhao Jing Chen Jing Hong Ma Source Type: research
Preclinical evaluation of a SARS-CoV-2 variant B.1.351-based candidate DNA vaccine
Vaccine. 2023 Sep 17:S0264-410X(23)01091-5. doi: 10.1016/j.vaccine.2023.09.021. Online ahead of print.ABSTRACTThe SARS-CoV-2 pandemic revealed the critical shortfalls of global vaccine availability for emergent pathogens and the need for exploring additional vaccine platforms with rapid update potential in response to new variants. Thus, it remains essential, for the present evolving SARS-CoV-2/Covid-19 and future pandemics, to continuously develop and characterize new and different vaccine platforms. Here, we describe an expression-optimized DNA vaccine candidate based on the SARS-CoV-2 spike protein of the Beta variant (...
Source: Vaccine - September 19, 2023 Category: Allergy & Immunology Authors: Ria Lassauni ère Charlotta Polacek Jeanette Linnea Tingstedt Anders Fomsgaard Source Type: research
A large survey on COVID-19 vaccination in patients with Parkinson's disease and healthy population
CONCLUSIONS: The COVID-19 vaccination rate was remarkably lower in PD patients than healthy individuals in China. The approved vaccines have shown an acceptable safety profile. Our findings would offer a reference to guide future clinical decision-making of COVID-19 vaccination and improve the immunization management of PD patients.PMID:37726180 | DOI:10.1016/j.vaccine.2023.09.002
Source: Vaccine - September 19, 2023 Category: Allergy & Immunology Authors: Chao Han Zhen Zhen Zhao Piu Chan Fang Li Chun Ling Chi Xin Zhang Yan Zhao Jing Chen Jing Hong Ma Source Type: research
Preclinical evaluation of a SARS-CoV-2 variant B.1.351-based candidate DNA vaccine
Vaccine. 2023 Sep 17:S0264-410X(23)01091-5. doi: 10.1016/j.vaccine.2023.09.021. Online ahead of print.ABSTRACTThe SARS-CoV-2 pandemic revealed the critical shortfalls of global vaccine availability for emergent pathogens and the need for exploring additional vaccine platforms with rapid update potential in response to new variants. Thus, it remains essential, for the present evolving SARS-CoV-2/Covid-19 and future pandemics, to continuously develop and characterize new and different vaccine platforms. Here, we describe an expression-optimized DNA vaccine candidate based on the SARS-CoV-2 spike protein of the Beta variant (...
Source: Vaccine - September 19, 2023 Category: Allergy & Immunology Authors: Ria Lassauni ère Charlotta Polacek Jeanette Linnea Tingstedt Anders Fomsgaard Source Type: research
Protocol for a living evidence synthesis on variants of concern and COVID-19 vaccine effectiveness
DISCUSSION: Evidence generated from our living evidence synthesis will be used to inform policy making, modelling, and prioritization of future research on the effectiveness of COVID-19 vaccines against VOC.PMID:37718186 | DOI:10.1016/j.vaccine.2023.09.012
Source: Vaccine - September 17, 2023 Category: Allergy & Immunology Authors: Nicole Shaver Melanie Katz Gideon Darko Asamoah Lori-Ann Linkins Wael Abdelkader Andrew Beck Alexandria Bennett Sarah E Hughes Maureen Smith Mpho Begin Doug Coyle Thomas Piggott Benjamin M Kagina Vivian Welch Caroline Colijn David J D Earn Khaled El Emam Source Type: research
COVID-19 vaccine effectiveness against hospitalizations in Paraguay, May 2021-April 2022: A test-negative design
CONCLUSIONS: This study contributes to our understanding of COVID-19 VE in Latin America and to global understanding of vaccines that have not been widely used in North America and Europe. VE estimates from Paraguay can parameterize models to estimate the impact of the national COVID-19 vaccination campaign in Paraguay and similar settings.PMID:37716830 | DOI:10.1016/j.vaccine.2023.09.015
Source: Vaccine - September 16, 2023 Category: Allergy & Immunology Authors: Sandra Irala Sarah Hamid Elena Penayo Fabiana Michel Paula Couto Cynthia Vazquez Mar ía José Ortega Chavely Dom ínguez Silvia Battaglia Marta Von Horoch Romeo Montoya Guillermo Sequera Francisco Nogareda Source Type: research
Vaccination coverage survey of children aged 1-3 years in Beijing, China, 2005-2021
CONCLUSION: The coverage level and service quality of routine immunization in Beijing were relatively high. However, as influenced by COVID-19 epidemics, both on-time and in-time vaccination rates decreased significantly, except for BCG and HepB. Under the background of COVID-19 pandemic, the keys to maintain high level of vaccination coverage include flexible immunization service time to ensure the guardians bringing their children for vaccination timely, and more attention from providers to the doses after children's first birthday.PMID:37709591 | DOI:10.1016/j.vaccine.2023.08.015
Source: Vaccine - September 14, 2023 Category: Allergy & Immunology Authors: Wen-Yan Ji Dong-Lei Liu Rui Yu Liang Miao Qian-Li Yuan Luo-Dan Suo Jian-Ping Yu Source Type: research
COVID-19 vaccine booster doses provide increased protection against COVID-19 hospitalization compared with previously vaccinated individuals: Interim findings from the REFORCO-Brazil real-world effectiveness study during Delta and Omicron
CONCLUSIONS: Our results support the use of AZD1222 and other adenoviral/mRNA vaccine boosters to maintain protection against COVID-19 hospitalization from Omicron subvariants, including in elderly and immunocompromised individuals at increased risk of accelerated waning or severe outcomes.PMID:37704499 | DOI:10.1016/j.vaccine.2023.08.085
Source: Vaccine - September 13, 2023 Category: Allergy & Immunology Authors: Wilhelmine Meeraus Anke L Stuurman Ilgaz Durukal Eduardo Conde-Sousa Andrew Lee Andr é Santa Maria B árbara Emoingt Furtado Mario Ouwens Christen M Gray Douglas Andreas Valverde Hugo Gomes da Silva Sylvia Taylor Source Type: research
